21 June 2022

During development, the very early embryo is thought to be developmentally unrestricted, being able to differentiate into both embryonic (foetus) and extraembryonic (placental) lineages. This unrestricted developmental potential is thought to be facilitated by the lack of any chromatin-based lineage-barriers, representing a "blank slate". However, it has remained enigmatic how such blank slate of totipotent-like cells is manifested.

To comprehensively profile the epigenetic state of human naive (totipotent-like) embryonic cells, international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. They observed a strong enrichment of the histone modification H3K27me3, which is deposited by polycomb repressive complex 2 (PRC2), and found this histone mark to be more abundantly present at the promotors of lineage-determining genes. By inhibiting PRC2, thereby preventing H3K27me3 deposition, the researchers observed enhanced formation of trophectoderm cells. Similarly, in a very recently developed human embryonic model called blastoids (see figure), they observed accelerated blastoid development and increased cavitation upon PRC2 inhibition, highlighting a role for PRC2 as a lineage gatekeeper during the earliest stages of human development. The results were published this week in Nature Cell Biology.

 

 

 

 

 

This new research opens up the ability to better control stem cell specialisation and blastoid development, which is useful for studying in the laboratory how the initial placental cells are formed. In the longer term, the new knowledge might improve our understanding of how embryos successfully implant in the uterus at the earliest stages of pregnancy, and how this can be misregulated.

Related news items


Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs

14 June 2022

The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma.

read more

European grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant

26 April 2022

The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.

read more

Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation published in Cellular and Molecular Life Sciences

20 April 2022

Lisa Huis in ‘t Veld, Nataschja Ho and colleagues from the team of Gosse Adema published in Cellular and Molecular Life Sciences that Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation.

read more

Rubicon grants awarded to three RIMLS researchers

19 April 2022

Three researchers have received Rubicon funding from NWO/ZonMw. This will enable Elke Muntjewerff, Laura de Vries and Laurens van de Wiel to do research at a foreign research institute for the next two years.

read more

ERC Proof of Concept Grant for Martijn Verdoes

8 March 2022

Martijn Verdoes, group leader Chemical Immunology at the department of Tumor Immunology, has been awarded an ERC Proof of Concept (PoC) Grant. The ERC PoC Grants are designed to support ERC grantees with the commercial or societal application of the results of their funded research.

read more

DeepRank: a deep learning framework for data mining 3D protein-protein interfaces

8 December 2021

Li Xue and colleagues recently published ''DeepRank, a deep learning framework for data mining 3D protein-protein structures'' in Nature Communications.

read more